Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Crizotinib cMS with Food and Esomeprazole
NCT03137134Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of crizotinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration, Area Under the Curve From Time Zero to Extrapolated Infinite Time and 1 more. Started Jun 2017; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03137134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137134.